KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Other Operating Expenses (2019 - 2025)

Novavax (NVAX) has 12 years of Other Operating Expenses data on record, last reported at $22.9 million in Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 37.52% year-over-year to $22.9 million; the TTM value through Dec 2025 reached $170.9 million, down 15.71%, while the annual FY2024 figure was $51.9 million, N/A changed from the prior year.
  • Other Operating Expenses reached $22.9 million in Q4 2025 per NVAX's latest filing, down from $118.5 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $434.6 million in Q3 2022 and bottomed at $14.1 million in Q1 2025.
  • Average Other Operating Expenses over 4 years is $101.3 million, with a median of $57.5 million recorded in 2023.
  • The widest YoY moves for Other Operating Expenses: up 124.19% in 2023, down 79.42% in 2023.
  • A 4-year view of Other Operating Expenses shows it stood at $181.8 million in 2022, then dropped by 14.74% to $155.0 million in 2023, then crashed by 76.34% to $36.7 million in 2024, then crashed by 37.52% to $22.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $22.9 million in Q4 2025, $118.5 million in Q3 2025, and $15.3 million in Q2 2025.